Recent Updates
Recently added Catalysts
IVVD Positive Sentiment

Invivyd to Participate in Upcoming September Investor Conferences

Key Takeaway: Invivyd, Inc. has announced its participation in three upcoming investor conferences in September 2026. CEO Marc W. Elia and management will engage with investors at the Citi Biopharma Conference, Cantor Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. Live webcasts of the events will be available on the company's investor website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is actively engaging with investors through multiple conferences.
  • The company showcases its commitment to transparency by hosting meetings.
  • Live webcasts of the events will be available for broader accessibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~11 mo
Medium dilution risk
Lead asset
VYD2311-SD
Phase 3 · COVID-19

Full Press Release Details

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 (Meetings Only) Location: New York, NY

2026 Cantor Global Healthcare Conference Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link) Meetings to Follow Location: New York, NY
H.C. Wainwright 28 th Annual Global Investment Conference Fireside Chat: Monday, September 14, 2026 at 5:00 PM ET (Webcast Link) Meetings Prior to Fireside Chat Location: New York, NY
Live webcasts of the fireside chats will be available via the investor section of Invivyd’s website at investors.invivyd.com and will be archived following each event.
The management team will host investor meetings at the conferences. Investors participating in these events who are interested in meeting with Invivyd management should contact their Citi, Cantor, or H.C. Wainwright representatives.
About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts: Media Relations (781) 208-0160 media@invivyd.com

Investor Relations (781) 208-1747 investors@invivyd.com

Frequently Asked Questions

What conferences will Invivyd participate in?

Invivyd will participate in Citi's Biopharma Conference, Cantor Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.

Who will represent Invivyd at the conferences?

Marc W. Elia, the CEO, along with other members of the management team, will represent Invivyd.

Will there be webcasts of the events?

Yes, live webcasts of the fireside chats will be available on Invivyd's investor website.

How can investors meet with Invivyd management?

Investors interested in meetings should contact their Citi, Cantor, or H.C. Wainwright representatives.

Last updated: Sep 8, 2026